时间基因组异质性指导复发性非小细胞肺癌的个性化治疗
Qiyu Fang1,2, Xiaoying Wan2, Angelica D'Aiello3
1Medical College of Soochow University, Suzhou, Jiangsu, China.
Frontiers in oncology
|July 28, 2023
概括
手术后非小细胞肺癌 (NSCLC) 瘤的遗传变化显著影响治疗的有效性. 了解这种时间遗传异质性对于改善患者的治疗结果和指导治疗选择至关重要.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 翻译研究是翻译研究.
背景情况:
- 辅助系统治疗对切除的非小细胞肺癌 (NSCLC) 患者提供了好处.
- 手术后复发仍然是一个重大挑战,影响长期生存.
- 鉴定原发性和复发性瘤之间的遗传变化对于优化治疗策略至关重要.
研究的目的:
- 调查原发性和复发性非小细胞肺癌 (NSCLC) 瘤之间的时间遗传异质性.
- 评估这些遗传转变对治疗结果的影响.
- 根据不断演变的瘤基因型确定潜在的治疗点.
主要方法:
- 下一代测序 (NGS) 用于分析组织样本和循环瘤DNA (ctDNA).
- 最初的手术样本的基因型与在术后复发时收集的样本进行了比较.
- 这项研究包括了45名患有匹配的原发性和复发性瘤的患者.
主要成果:
- 在复发时,EGFR状态在37.8%的患者中发生了切换.
- 持续敏感的EGFR突变显示出最高的部分反应 (72.2%) 和最长的无进展生存期 (17个月).
- 基因型变化,包括野生型转变为突变型或共突变的出现,与较差的治疗结果有关.
结论:
- 主要和复发性NSCLC瘤之间的时间遗传异质性是常见的.
- 这些基因型变化显著影响后续治疗的疗效,包括EGFR TKI和化疗.
- 了解瘤进化对于NSCLC个性化治疗方法至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


